



## **SOUTHWESTERN**

THE UNIVERSITY OF TEXAS  
SOUTHWESTERN MEDICAL CENTER  
AT DALLAS

**Philip E. Thorpe, Ph.D.**  
Professor  
The Serena S. Simmons Distinguished Chair  
in Cancer Immunopharmacology

**Department of Pharmacology**  
Nancy B. and Jake L. Hamon Center  
for Therapeutic Oncology Research

Mr. Richard U. Rodriguez  
Technology Analyst  
Office of Legal Affairs and  
Technology Transfer  
UT Southwestern

RE: UTSD:549 — Immunotherapy of Cancer with Antibodies to a Marker of  
Tumor Vascular Endothelium

Dear Mr. Rodriguez:

The monoclonal antibodies, 35B9b against phosphatidylserine and D11A4 against cardiolipin, were sent to Dr. Sophia Ran and myself by Dr. Neal Rote of Wright State University, Ohio, without any commercial obligations or material transfer agreement. We agreed to include Dr. Rote as a coauthor on primary manuscripts but this is the only obligation of which we are aware.

The first shipment of antibodies was made on . The idea of using the antibodies for immunotherapy that is the subject of the above invention came from the surprising observation by Dr. Ran that administration of Dr. Rote's anti-phosphatidylserine antibody to tumor bearing mice caused selective thrombosis of tumor blood vessels.

Yours sincerely,

Philip E. Thorpe, Ph.D.  
Professor of Pharmacology

cc: Dr. Sophia Ran  
Mr. Ray Wheatley  
✓ Ms. Shelley Fussey